Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-846-8 | CAS number: 68609-97-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: dermal
Some information in this page has been claimed confidential.
Administrative data
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1997
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Reference
- Endpoint:
- one-generation reproductive toxicity
- Remarks:
- based on generations indicated in Effect levels
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP Guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.4420 (Preliminary Developmental Toxicity Screen)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD®(SD)BR
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Sixty sexually mature, virgin female Cr1:CD® (SD)BR rats were received in good health from Charles River Laboratories, Inc., Portage, Michigan, on October 17, 1996. The animals were approximately 10 weeks old. Upon receipt, each animal was observed by a qualified technician. The animals were initially weighed on the day following receipt. All animals were uniquely identified by a Monel metal eartag displaying the animal number and housed for 12 days for acclimation purposes. During this time, the animals were observed twice daily for mortality and moribundity.
ANIMAL HOUSING
Upon arrival and until pairing, all animals were individually housed in clean, wire-mesh cages suspended above cage-board. All animals were maintained in accordance with the "Guide for the Care and Use of Laboratory Animals" (NIH, 1985). The animal facilities at WIL Research Laboratories, Inc., are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).
DIET. DRINKING WATER AND MAINTENANCE
The basal diet used in this study was PMI Feeds, Inc.© Certified Rodent LabDiet© 5002. This diet is a certified feed with appropriate analyses performed by the manufacturer and provided to WIL Research Laboratories, Inc. Municipal water supplying the facility is sampled for contaminants according to Standard Operating Procedures. The results of these analyses are maintained at WIL Research Laboratories, Inc. Contaminants were not present in animal feed or water at concentrations expected to interfere with the objectives of this study. Drinking water delivered by an automatic watering system and the basal diet were provided ad libitum throughout the acclimation period and during the study.
F. ENVIRONMENTAL CONDITIONS
All animals were housed throughout the acclimation period and during the study in an environmentally-controlled room. Controls were set to maintain a temperature of 72° ± 4°F and a relative humidity of 30-70%. Room temperature and relative humidity were recorded daily. Actual recorded ranges for temperature and relative humidity were 71.6°F to 72.2°F and 26.4% to 45.5 %, respectively, during the study period. The occasional deviations from the set humidity levels would not be expected to have an adverse effect on the outcome of the study. Light timers were calibrated to provide a 12-hour light/12-hour dark photoperiod. Air handling units were set to provide approximately 10 fresh air changes per hour. - Route of administration:
- dermal
- Vehicle:
- acetone
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
PREPARATION
A sufficient amount of the vehicle, acetone, was dispensed into a labeled storage container for administration to the control group. A magnetic stir bar was added and the solution was stirred continuously throughout the dispensing procedure. A sufficient amount of vehicle was dispensed into daily aliquots for dose administration.
Each test article formulation was prepared by weighing the appropriate amount of alkyl glycidyl ethers into a tared, precalibrated, labeled storage container and adding an appropriate amount of vehicle. A magnetic stir bar was added to each formulation, and the formulations were stirred continuously throughout the dispensing procedure. The preparations were dispensed into daily aliquots for dose administration. The test article
formulations were prepared once during the study (November 4, 1996) and were stored at room temperature, capped with nitrogen. The formulations visually inspected by the study director prior to the initiation of dosing on November 4, 1996, and were found to be acceptable for dose administration.
VEHICLE
The vehicle control article used for dose administration to the vehicle control group and in preparation of the test mixtures was acetone received from Fisher Scientific Company, Pittsburgh, Pennsylvania. - Details on mating procedure:
- STUDY DESIGN
I. Acclimation Period
II. Untreated Females Paired with Untreated Resident Males
III. Animals Observed Daily, Body Weights and Food Consumption Recorded at Appropriate Intervals
IV. Mated Females/Group (1-6) Treated Once Daily (6 Hours/Day) From Gestation Days 6-15
V. Laparohysterectomies Performed on Gestation Day 20; Gravid Uterine Weights Recorded
VI. External Fetal Morphological Examination - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- PREPARATION OF DOSING SOLUTIONS:
PREPARATION
A sufficient amount of the vehicle, acetone, was dispensed into a labeled storage container for administration to the control group. A magnetic stir bar was added and the solution was stirred continuously throughout the dispensing procedure. A sufficient amount of vehicle was dispensed into daily aliquots for dose administration.
Each test article formulation was prepared by weighing the appropriate amount of alkyl glycidyl ethers into a tared, precalibrated, labeled storage container and adding an appropriate amount of vehicle. A magnetic stir bar was added to each formulation, and the formulations were stirred continuously throughout the dispensing procedure. The preparations were dispensed into daily aliquots for dose administration. The test article
formulations were prepared once during the study (November 4, 1996) and were stored at room temperature, capped with nitrogen. The formulations visually inspected by the study director prior to the initiation of dosing on November 4, 1996, and were found to be acceptable for dose administration.
VEHICLE
The vehicle control article used for dose administration to the vehicle control group and in preparation of the test mixtures was acetone received from Fisher Scientific Company, Pittsburgh, Pennsylvania. - Duration of treatment / exposure:
- Gestation days 6 through 15.
- Frequency of treatment:
- six hours each day
- Details on study schedule:
- STUDY DESIGN
I. Acclimation Period
II. Untreated Females Paired with Untreated Resident Males
III. Animals Observed Daily, Body Weights and Food Consumption Recorded at Appropriate Intervals
IV. Mated Females/Group (1-6) Treated Once Daily (6 Hours/Day) From Gestation Days 6-15
V. Laparohysterectomies Performed on Gestation Day 20; Gravid Uterine Weights Recorded
VI. External Fetal Morphological Examination
Approximately 24 hours before the initial application of test article, the back (approximately 10% of the body surface) of each rat was clipped with Oster® small animal clippers. Clipping was repeated, if necessary, during the treatment period.
The test article, alkyl glycidyl ethers, was applied to the clipped intact dorsal skin of each test animal for six hours per day, from gestation days 6 through 15. The application sites were not occluded or abraded. Individual doses were calculated based on the most recent individual body weight recorded prior to test article application. All animals were dosed at approximately the same time each day.
The concurrent control group was dosed with the vehicle control article following procedures identical to those described for the treated groups.
During the exposure period, oral ingestion of the control and test articles was prevented by placing an Agar™ collar on each animal. Following the 6-hour exposure period, the collars were removed and the application sites were washed with a mild concentration of Ivory soap, then towel-dried. (The animals were acclimated to the collars prior to breeding according to the protocol. After breeding, the animals were fitted with collars for 6-hours per day throughout the pre-administration phase of gestation days 0-5 and during the treatment period. Acclimation to collars was suspended for each female upon pairing until confirmation of mating.)
The following diagram represents the study group assignment:
Group...............Dose Level.............Dose Concentration........Dose Volume.......Number of females
.......................... (mg/kg/day)................. (mg/ml)....................(ml/kg)
1........................0 (vehicle control).....................0.........................1........................8
2............................1................................................1........................1........................8
3..........................10.............................................10........................1........................8
4..........................50.............................................50........................1....................... 8
5........................100..........................................100........................1........................8
6........................200......................................... 200........................1........................8 - No. of animals per sex per dose:
- 8
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
DETAILED CLINICAL OBSERVATIONS: Yes
CLINICAL OBSERVATIONS AND SURVIVAL
All rats were observed twice daily for moribundity and mortality. Individual detailed clinical observations were recorded from gestation days 0 through 20 (prior to compound administration during the dosing period). Clinical findings observed at the time of dosing, if present, were also recorded. All animals were observed for signs of toxicity approximately one hour following dosing; no significant findings were recorded at the post-dosing observation periods.
DERMAL IRRITATION
Application sites were examined for erythema, edema and other dermal findings once daily prior to treatment (gestation days 6 through 15) and daily thereafter. Erythema and edema were evaluated on a four step grading system of very slight, slight, moderate and severe. Other dermal findings, if present, were noted.
BODY WEIGHT: Yes
Individual maternal body weights were recorded on gestation days 0, 6-16 (daily) and 20. A group mean body weight was calculated for each of these days. Mean body weight changes were calculated for each corresponding interval and also for gestation days 6-9, 9-12, 12-16, 6-16 and 0-20.
Gravid uterine weight was collected and net body weight (the day 20 body weight minus the weight of the uterus and contents) and net body weight change (the day 0-20 body weight change minus the weight of the uterus and contents) were calculated and presented for each gravid female at the scheduled laparohysterectomy.
FOOD CONSUMPTION: Yes
Individual maternal food consumption was recorded on the corresponding gestation body weight days. The amounts of food consumed were calculated for the corresponding body weight change intervals and were reported as g/animal/day and g/kg/day.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
Ovaries and uterine content
GESTATION DAY 20 LAPAROHYSTERECTOMY
All maternal animals were euthanized by carbon dioxide inhalation on gestation day 20. The thoracic, abdominal and pelvic cavities were opened by a ventral midline incision and the contents were examined. In all instances, the post mortem findings were correlated with the ante mortem comments and any abnormalities were recorded. The uterus and ovaries were excised. The number of corpora lutea on each ovary was recorded. The trimmed uterus was weighed, opened and the number and location of all fetuses, early and late resorptions and the total number of implantation sites were recorded. The individual uterine distribution of implantation sites was documented using the following procedure. All implantation sites, including resorptions, were numbered in consecutive order beginning with the left distal to the left proximal uterine horn, noting the position of the cervix, and continuing from the right proximal to the right distal uterine horn.
Uteri with no macroscopic evidence of nidation were excised, opened and subsequently placed in 10% ammonium sulfide solution for detection of early implantation loss as described by Salewski (1964, Archiv. Fur Exper. Pathologie und Pharm. 247:367. Maternal tissues were retained only as deemed necessary by the gross findings.
- Litter observations:
- The number of corpora lutea on each ovary was recorded. The trimmed uterus was weighed, opened and the number and location of all fetuses, early and late resorptions and the total number of implantation sites were recorded. The individual uterine distribution of implantation sites was documented using the following procedure. All implantation sites, including resorptions, were numbered in consecutive order beginning with the left distal to the left proximal uterine horn, noting the position of the cervix, and continuing from the right proximal to the right distal uterine horn.
Uteri with no macroscopic evidence of nidation were excised, opened and subsequently placed in 10% ammonium sulfide solution for detection of early implantation loss as described by Salewski (1964, Archiv. Fur Exper. Pathologie und Pharm. 247:367. Maternal tissues were retained only as deemed necessary by the gross fmdings. - Postmortem examinations (parental animals):
- POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
Ovaries and uterine content
GESTATION DAY 20 LAPAROHYSTERECTOMY
All maternal animals were euthanized by carbon dioxide inhalation on gestation day 20. The thoracic, abdominal and pelvic cavities were opened by a ventral midline incision and the contents were examined. In all instances, the post mortem findings were correlated with the ante mortem comments and any abnormalities were recorded. The uterus and ovaries were excised. The number of corpora lutea on each ovary was recorded. The trimmed uterus was weighed, opened and the number and location of all fetuses, early and late resorptions and the total number of implantation sites were recorded. The individual uterine distribution of implantation sites was documented using the following procedure. All implantation sites, including resorptions, were numbered in consecutive order beginning with the left distal to the left proximal uterine horn, noting the position of the cervix, and continuing from the right proximal to the right distal uterine horn.
Uteri with no macroscopic evidence of nidation were excised, opened and subsequently placed in 10% ammonium sulfide solution for detection of early implantation loss as described by Salewski (1964, Archiv. Fur Exper. Pathologie und Pharm. 247:367. Maternal tissues were retained only as deemed necessary by the gross fmdings. - Postmortem examinations (offspring):
- FETAL MORPHOLOGICAL EXAMINATION
A detailed external examination of each fetus was conducted to include, but was not limited to, the eyes, palate and external orifices. Each fetus was then sexed, weighed, euthanized by an intrathoracic injection of pentobarbital and discarded. Findings were recorded as either developmental variations or malformations. Crown-rump measurements were recorded for late resorptions, if present, and the tissues were discarded.
- Statistics:
- All analyses were conducted using two-tailed tests for a minimum significance level of 5%, comparing each treated group to the vehicle control group. Each mean was presented with the standard deviation (S.D.) and the number of animals (N) used to calculate the mean. The statistical tests were performed by a Digital® MicroVAX® 3400 computer (with appropriate programming) in this laboratory and are referenced in the study report.
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- effects observed, treatment-related
- Description (incidence and severity):
- Dermal irritation (Erythema, edema and desquamation) at the application site was observed in the 50, 100 and 200 mg/kg/day groups.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- effects observed, treatment-related
- Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- 200 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No maternal toxicity or developmental toxicity was apparent at any dose level.
- Dose descriptor:
- NOEL
- Remarks:
- dermal irritation
- Effect level:
- 10 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Dermal irritation (Erythema, edema and desquamation) at the application site was observed in the 50, 100 and 200 mg/kg/day groups.
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity
- Generation:
- F1
- Effect level:
- 200 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: One control group fetus had macroglossia. No other external malformations and no external developmental variations were observed in fetuses in this study.
- Critical effects observed:
- no
- Reproductive effects observed:
- not specified
- Conclusions:
- In conclusion, localized dermal irritation was observed in a dose-related manner at dose levels of 50, 100 and 200 mg/kg/day. No maternal toxicity or developmental toxicity was apparent at any dose level. Based on the results of this study, the no-effect level for dermal irritation was considered to be 10 mg/kg/day and the no-effect level for maternal toxicity and developmental toxicity was considered to be 200 mg/kg/day.
- Executive summary:
All maternal animals survived to the scheduled necropsy on gestation day 20.
The only treatment-related clinical sign observed was vocalization at the time of dosing in the 50, 100 and 200 mg/kg/day groups between gestation days 7 and 15.
Dermal irritation at the application site was observed in the 50, 100 and 200 mg/kg/day groups. Erythema, edema and desquamation occurred in all animals in these groups (with the exception of no edema for one 50 mg/kg/day group animal). The severity and/or time of onset for these findings were dose-related. More severe signs of dermal irritation were noted only at dose levels of 100 and 200 mg/kg/day. These included fissuring, eschar formation and atonia in two to five 100 mg/kg/day group animals and in all 200 mg/kg/day group animals. The severity of erythema and edema and the frequency of fissuring, eschar formation and atonia tended to decrease during the post-treatment period. No test article-related dermal irritation was noted at the application site in the 1
and 10 mg/kg/day groups.
Mean body weights, body weight gains, net body weights, net body weight gains and gravid uterine weights in the 1, 10, 50, 100 and 200 mg/kg/day groups were similar to the control group values. Food consumption, assessed as g/animal/day and g/kg/day, in the treated groups was unaffected by test article administration.
At the scheduled necropsy, no test article-related internal findings were observed at any dose level. Findings at the application site were limited to scabbing in two and six animals in the 100 and 200 mg/kg/day groups, respectively, and thickening in two of these high dose group animals.
Intrauterine growth and survival were unaffected by test article administration at any dose level. Parameters evaluated included postimplantation loss, mean fetal body weight, viable litter size, fetal sex ratios and the mean numbers of corpora. lutea and implantation sites. Fetuses (litters) available for external morphological evaluation numbered 99(7), 110(8), 91(7), 79(7), 95(7) and 87(6) in the control, 1, 10, 50, 100 and 200 mg/kg/day groups, respectively. One control group fetus had macroglossia. No other external malformations and no external developmental variations were observed in fetuses in this study.
In conclusion, localized dermal irritation was observed in a dose-related manner at dose levels of 50, 100 and 200 mg/kg/day. No maternal toxicity or developmental toxicity was apparent at any dose level. Based on the results of this study, the no-effect level for dermal irritation was considered to be 10 mg/kg/day and the no-effect level for maternal toxicity and developmental toxicity was considered to be 200 mg/kg/day.
All animals survived to the scheduled necropsy on gestation day 20. In the 50, 100 and 200 mg/kg/day groups, four, five and six animals, respectively, were noted to vocalize at the time of dosing between gestation days 7 and 15. No other clinical signs that could be attributed to treatment with the test article were observed at any dose level. Other findings in the treated groups were limited to hair loss or scabbing on various body surfaces in single animals. No relationship to treatment was evident.
DERMAL IRRITATION
Erythema, edema and desquamation occurred in all animals in these groups (with the exception of no edema for one 50 mg/kg/day group animal). The severity and/or time of onset for these findings were dose-related. More severe signs of dermal irritation were noted only at dose levels of 100 and 200 mg/kg/day. These included fissuring, eschar formation and atonia in two to five 100 mg/kg/day group animals and in all 200 mg/kg/day group animals. The severity of erythema and edema and the frequency of fissuring, eschar formation and atonia tended to decrease during the post-treatment period.
Erythema was noted for all animals in the 50, 100 and 200 mg/kg/day groups beginning gestation days 7 or 8 (one to two days following the initiation of dosing) and persisting to study termination (gestation day 20). Erythema was graded as very slight to moderate in all three groups. Severe erythema was noted only at dose levels of 100 and 200 mg/kg/day beginning on gestation day 13 or 14 and continuing through gestation day 17 (100 mg/kg/day) or 19 (200 mg/kg/day). With the exception of female No. 57633 in the 50 mg/kg/day group, all animals in the 50, 100 and 200 mg/kg/day group had edema, generally graded as very slight in the 50 mg/kg/day group and as very slight to slight in the 100 and 200 mg/kg/day groups. Edema was first noted on gestation day 10 in the 50 mg/kg/day group and occurred sporadically thereafter. In the 100 and 200 mg/kg/day groups, edema was noted in all animals by gestation days 11 and 9, respectively, and generally persisted throughout the remainder of the treatment period and into the post-treatment period. Edema was not observed in either group on gestation day 20. Both erythema and edema tended to decrease in severity by the end of the post-treatment period (gestation day 20). Desquamation was observed in all animals in the 50, 100 and 200 mg/kg/day groups beginning gestation 12-16, 11-14 and 11-14, respectively. This finding persisted through gestation day 20.
Fissuring occurred in the 100 and 200 mg/kg/day groups beginning on gestation days 11 and 10, respectively. Eschar formation was first noted in these groups on gestation days 15 and 12, respectively. Atonia was first noted on gestation day 16 in the 100 mg/kg/day group and on gestation day 14 in the 200 mg/kg/day group. These findings were noted sporadically throughout the remainder of the study; however, the frequency of these findings tended to decrease during the post-treatment period (gestation days 16-20).
In the 10 mg/kg/day group, two females (nos. 57617 and 57655) had very slight erythema on gestation days 14 through 16. These transient occurrences in two animals were not considered to be definitive indications of test article- related dermal irritation. No other dermal findings were observed at a dose level of 10 mg/kg/day. No dermal findings were noted in the control or 1 mg/kg/day groups.
BODY WEIGHTS AND GRAVID UTERINE WEIGHTS
Mean body weights and body weight gains throughout gestation, net body weights, net body weight gains and gravid uterine weights in the 1, 10, 50, 100 and 200 mg/kg/day groups were similar to the control group values. Differences were slight and were not statistically significant.
FOOD CONSUMPTION
Food consumption, evaluated as g/animal/day and g/kg/day, in the 1, 10, 50, 100 and 200 mg/kg/day groups was unaffected by test article administration. The only statistically significant difference between the control and treated groups during the comprehensive intervals was a slightly decreased (p <0.05) g/kg/day food consumption value in the 1 mg/kg/day group during gestation days 12-16. Similar decreases were not observed at the higher dose levels, and no relationship to treatment was apparent.
NECROPSY DATA
At the scheduled necropsy, test article-related findings were limited to observations at the application site. Two and six animals in the 100 and 200 mg/kg/day groups, respectively, had scabbing at the application site. Two of these 200 mg/kg/day group animals also had thickening at the application site. No internal findings related to the test article were observed at any dose level. Female no. 57658 in the 200 mg/kg/day group had dark red lungs. All other animals were internally normal.
GESTATION DAY 20 LAPAROHYSTERECTOMY DATA
Intrauterine growth and survival were unaffected by test article administration at any dose level. Parameters evaluated included postimplantation loss, mean fetal body weights, viable litter size, fetal sex ratios and the mean numbers of corpora lutea and implantation sites. None of the differences from the control group were statistically significant.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- Deviations:
- no
- GLP compliance:
- yes
Test material
- Details on test material:
- Alkyl (C12-C14) glycidyl ether
Label: Epoxide 8
51% C12 Glycidyl ether
21% C14 Glycidyl ether
5% C16 Glycidyl ether
13% N +1's
4% alpha addition Products
94% total active (label claim)
- Physical state: Clear colorless liquid
- Storage condition of test material: ambient
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- acetone
- Details on exposure:
- Continuous (5 days/week for 13 weeks)
- Duration of treatment / exposure:
- Continuous (5 days/week for 13 weeks)
- Frequency of treatment:
- Continuous (5 days/week for 13 weeks)
- Details on study design:
- One repeated dose study was conducted to evaluate the subchronic dermal toxicity potential of C12-C13 alkyl glycidyl ether (AGE) in Fischer 344 rats following a 5 days per week dosing regimen for approximately 13 weeks, according to the OECD guideline 411 and in compliance with GLP (McGuirk, 1997). A range finding study was conducted in which two rats/sex/dose level were dosed dermally with 0, 10, 100, or 1000 mg/kg/day alkyl glycidyl ether (AGE) in acetone, 5 days/week for up to a total of 10 applications. In-life observations and dermal scoring indicated an ungroomed appearance in high-dose group rats; erythema, edema, scaling/fissuring and scabs in high and middle-dose group rats and slight scaling in low dose group rats.
Four doses of 1000 mg/kg/dayexceeded the maximum-tolerated dose as defined by loss of integrity of the epidermis. Grossly, the skin of high-dose rats appeared scaly, thickened and was ulcerated. Microscopically, the response consisted of epidermal hyperplasia with hyperkeratosis and parakeratosis along with hyperplasia of the sebaceous glands with ulceration, inflammation and edema. The epidermal response was similar at 100 mg/kg/day, however the epidermis remained intact. Treatment-related effects in low dose rats were limited to slight scaling at the dermal test site. Based on the results of the range finding study, non-occluded dermal doses of 0, 1, 10, or 100 mg/kg/day AGE in acetone were administered to ten rats/sex/dose level 5 days/week for 13 weeks. Standard toxicologic parameters were evaluated.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related changes in clinical or ophthalmologic observations, body weights, feed consumption or clinical pathology during the thirteen-week study.Treatment-related gross and histopathologic lesions were limited to the skin of high-dose rats. Applications of 100 mg/kg/day reached the maximum-tolerated dose defined by the USEPA (1988) with a definitive, uniform reaction at the dermal treatment site consisting of epidermal hyperplasia, hyperkeratosis, sebaceous gland hyperplasia and a mild inflammatory response. The response was similar after 2 or 13 weeks, although the response was equivocally of greater severity after 2 weeks. Crusts, underlain by intact hyperplastic epidermis, were present after 2 weeks but not after 13 weeks. Treatment-related effects in 10 mg/kg/day rats were limited to slight scaling, although histopathologically the skin appeared normal. The no-observed effect level for local effects was 1 mg/kg/day. As no systemic effect was observed in all the groups tested, the NOAEL for systemic effects was 100 mg/kg/d.
- Dermal irritation:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 1 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- food consumption and compound intake
- food efficiency
- gross pathology
- ophthalmological examination
- Dose descriptor:
- LOEL
- Effect level:
- 10 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Treatment-related in-life effects in 10 mg/kg/day rats were limited to slight scaling, although histopathologically the skin appeared normal.
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies